Cannabigerol (CBG) – The Precursor the Other Cannabinoids Come From

Cannabigerol carries the nickname mother cannabinoid, and for once the nickname holds up. Its acid form is where the precursors of THC, CBD and CBC branch off, making it the junction of the whole cannabinoid pathway. Yet a mature drug-type flower contains very little of it, because the plant has largely spent the precursor by then. How much survives comes down to genetics, harvest timing and, to a smaller degree, how the crop is fed.

Quick facts

Why the plant makes CBGA and not CBG

The plant produces the acid form only. The route starts from a short-chain fatty acid, runs through olivetolic acid, and ends when an enzyme transfers the geranyl group to form cannabigerolic acid. Only then do the three cannabinoid synthases step in and shape it into the acid precursors of the familiar compounds.

Neutral CBG arises from that acid through decarboxylation, the loss of the carboxyl group under heat or light. It is therefore itself a conversion product and never a starting material. The common phrasing that CBG turns into THC skips two steps: what is converted is the acid, and the neutral forms appear at an entirely different point.

How much CBG a flower actually holds

In a field trial sampling five hemp cultivars weekly, total CBG at full maturity ranged from 0.189 to 0.260 % of dry matter, while the same plants carried between 4.5 and 10.3 % CBD. A balanced chemotype carrying both THC and CBD showed values of 0.6 to 0.86 % instead. The room below the one-percent mark is therefore considerable, and it depends on chemotype rather than on cultivation.

A conspicuously high residual value in a THC or CBD dominant cultivar is no mark of quality. It means either that the crop was cut early or that the relevant synthase is not fully functional, and both come at the expense of the intended compound.

Chemotype IV: plants that keep the precursor

Some plants accumulate CBGA because the conversion never happens. Crossing trials show the trait is inherited as a single recessive gene, and the suspected cause is a variant of tetrahydrocannabinolic acid synthase carrying one base substitution that probably leaves the enzyme unable to work. That substitution can serve as a molecular marker in breeding, freeing selection from laboratory analysis.

Such plants form chemotype IV, whose threshold is described in the article on chemotype. A protected CBG-dominant cultivar is documented at above 5 % CBG with under 0.1 % each of THC and CBD. Higher figures circulating in the trade could not be checked against any analysis.

What actually shifts CBG content

Timing matters most. In the field trial above, CBG rose as the flowers matured, peaked only in the seventh week after anthesis, and then dropped by 43.5 to 65.3 % within two weeks. The idea of an early precursor peak that has to be caught before conversion does not match this measurement.

Of the cultivation measures tested, only a 15 % increase in nitrogen, phosphorus and potassium raised CBG in the flowers, and it did so alongside a 41 % gain in shoot mass. Humic acid lowered it, despite being marketed on the opposite promise. Drought stress in early flowering shifted the ratio towards CBG but let CBD and THC collapse by 70 to 80 %, which is a redistribution rather than a gain.

After the cut, total content barely moves. Drying and curing only shift the balance between acid and neutral form, and three weeks of curing in the dark converted under 2 % unless the material had been dried hot beforehand.

What is known about the effects

Human evidence is thin. One double-blind, placebo-controlled trial with 34 healthy adults examined acute effects on anxiety, stress and mood as the first published clinical study of the compound. A critical review characterises the available human data as largely confined to pilot studies, often using multi-compound preparations and lacking randomised trials of isolated CBG with primary efficacy endpoints. Adverse effects on the liver have also been reported at high doses. Anyone buying CBG products is buying a substance with a plausible backstory and thin evidence.

Sources